GlassScriptPhysician profile
Mohit Mody
NPI 1124413919
$655.71
in general payments reported to CMS, 2019-2025
13 companies · $14.39 in 2025
The $14.39 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $336 · 2020: $97.39 · 2021: $169 · 2023: $39.00 · 2025: $14.39.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $39.00 · Food and Beverage: $14.39.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $39.00 |
| Food and Beverage | $14.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $225.14 | 2019-2025 | |
| Gilead Sciences, INC. | $125.93 | 2021 | |
| Allergan, INC. | $68.86 | 2019 | |
| Glaxosmithkline, LLC. | $43.19 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.16 | 2020-2021 | |
| Becton, Dickinson and Company | $39.00 | 2023 | |
| Insmed, INC. | $29.00 | 2019 | |
| Viiv Healthcare Company | $14.98 | 2020 | |
| Shire North American Group INC | $14.63 | 2019 | |
| Amgen INC. | $14.48 | 2019 | |
| Alnylam Pharmaceuticals INC. | $13.96 | 2019 | |
| Csl Behring | $13.70 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $11.68 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohit Mody listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.